Zopapogene imadenovec not checked
Precigen, Inc · PRGN-2012
FollowEvery change as it happens, and a Monday email
Trials
3 active
3 in total
What this is
- How it works
- A gene therapy: delivers a gene into the patient's cells so they make a protein they lack.-gene: gene therapy substances WHO name stem
- How it’s given
- “Zopa will be administered as 4 subcutaneous administrations over a 12-week interval.”In the company’s words, NCT06538480 on ClinicalTrials.gov
- Tested for
- Recurrent Respiratory Papillomatosis (2 trials), Papillomaviridae (2 trials), Papillomavirus Infections (2 trials), Papillomavirus Infection, Recurrent Respiratory Papillomatosis (RRP), Juvenile-onset Recurrent Respiratory Papillomatosis
- Main trialPhase 4
- “This open-label study evaluates safety, vector shedding, and retreatment efficacy of Zopapogene imadenovec (Zopa) in adults with recurrent respiratory papillomatosis (RRP). Two cohorts will be enrolled (n=30): Cohort 1 to assess the magnitude and duration of adenoviral vector shedding in urine, feces, skin, and nasal tissue; Cohort 2 to assess the complete response rate following retreatment.”In the company’s words, NCT06538480 on ClinicalTrials.gov
- Other names
- PRGN-2012
Other drugs for Papillomavirus Infections
- VP-102Verrica Pharmaceuticals Inc. · Phase 3
- CervavacSerum Institute of India Pvt. Ltd. · Phase 3
- V503Merck & Co. · Phase 3
- 9-valent Human Papillomavirus Recombinant VaccineShanghai Bovax Biotechnology Co., Ltd. · Phase 3
- GardasilMerck & Co. · Phase 3
- 11-valent recombinant human papilloma virus vaccineNational Vaccine and Serum Institute, China · Phase 3
Coming up2
- 2 Dec 2027Phase 4 trial completes · ClinicalTrials.gov
- Jan 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | 2 Dec 2027 | Zopa Retreatment and Vector Shedding in Adults With RRP | |
| Phase 3Not yet recruiting | Jan 2029 | Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in Children | |
| Phase 1/2Active, not recruiting | 5 Jun 2024 | Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026